Abstract
In order to explore the neuroprotective and crossspecies
activities of.C-peptide on type 1 diabetic
neuropathy, spontaneously diabetic BB/W-rats were
given increasing doses of human recombinant Cpeptide
(hrC-peptide). Diabetic rats received 10, 100,
500, or 1000 μg of hrC-peptide/kg body weight/
day from onset of diabetes. After 2 months of hrC-peptide
administration, 100 μg and greater doses
completely prevented the nerve conduction defect,
which was associated with a significant but incomplete
prevention of neural